U.S., Aug. 23 -- ClinicalTrials.gov registry received information related to the study (NCT07137390) titled 'Phase Ib/II Trial of Regorafenib Plus Lorigerlimab as Neoadjuvant Therapy for Patients With pMMR/MSS, Resectable, Lung-limited Metastatic Colorectal Cancer' on Aug. 15.

Brief Summary: To apply its findings as rationale needed for a subsequent registration trial towards a novel indication for systemic treatment of resectable, lung-limited metastatic CRC.

Study Start Date: Feb. 28, 2026

Study Type: INTERVENTIONAL

Condition: Colorectal Cancer

Intervention: DRUG: Regorafenib

Given Orally

DRUG: Lorigerlimab

Given Orally

Recruitment Status: NOT_YET_RECRUITING

Sponsor: M.D. Anderson Cancer Center

Published by HT Digital Content...